Thinking of joining a study?

Register your interest

Become a volunteer?

NCT06237062 | RECRUITING | Migraine

Migraine Survey in Gulf Region
Sponsor:

Novartis Pharmaceuticals

Brief Summary:

The objective of this study is to evaluate the effect of erenumab on medication-specific treatment satisfaction in patients newly started on erenumab over 12 weeks

Condition or disease

Migraine

Intervention/treatment

erenumab

Detailed Description:

This is a longitudinal prospective descriptive primary data collection using a 20 min online survey. Patients will be selected by investigators (general neurologists, headache/migraine specialists) in primary care clinics and hospitals. After fulfilling the inclusion criteria, the patient will be asked to sign an online informed consent. A 5 min screener will follow after which the patient will be directed through a link to the full survey. The duration of data collection will be for 6 months since the start of survey rolling in each site across centers in the Gulf Region.

Study Type : OBSERVATIONAL
Estimated Enrollment : 200 participants
Official Title : Real-world Experience of Patients Newly Started on Erenumab in the Gulf Region: a Longitudinal Prospective Observational Study
Actual Study Start Date : 2024-06-05
Estimated Primary Completion Date : 2025-03-30
Estimated Study Completion Date : 2025-03-30

Information not available for Arms and Intervention/treatment

Ages Eligible for Study: 18 Years to 100 Years
Sexes Eligible for Study: ALL
Accepts Healthy Volunteers:
Criteria
Inclusion Criteria
  • * EM\& CM (with or without Medication Overuse Headache (MOH)) patients
  • * Newly Started on erenumab either 70 mg or 140 mg (first dose received within 1 month prior study enrollment and baseline endpoints collection)
  • * Ability to receive 3 monthly doses of erenumab.
  • * Age more than 18 years
  • * Males and Females
  • * Allowing the patients to be stable on 1 adjunctive migraine preventive medication (if present)
  • * Agreed to be included in the study and signed informed consent
Exclusion Criteria
  • * Less than 18 years
  • * Age at onset of Migraine more than 50 years
  • * Any contraindications to the start of erenumab as per label
  • * Refusal to sign informed consent
  • * Inability to participate or restricted access to the online survey
  • * Enrolled in an interventional migraine-related study at the time of the study enrollement
Migraine Survey in Gulf Region

Location Details

NCT06237062

Please Choose a site

How to Participate

Want to participate in this study, select a site at your convenience, send yourself email to get contact details and prescreening steps.

Locations

RECRUITING

United Arab Emirates,

Novartis Investigative Site

Abu Dhabi, United Arab Emirates,

RECRUITING

United Arab Emirates,

Novartis Investigative Site

Ras Al Khaimah, United Arab Emirates,